← Back to Cypherpunk Technologies Stock
Cypherpunk Technologies (CYPH) News
https://www.investing.com/news/company-news/leap-therapeutics-shareholders-elect-directors-approve-proposals-93CH-3510818
https://www.investing.com/news/company-news/hc-wainwright-retains-buy-rating-on-leap-therapeutics-stock-cuts-pt-to-550-93CH-3439784
Leap Therapeutics (NASDAQ: LPTX ) just reported results for the first quarter of 2024. Leap Therapeutics reported earnings per share of -51 cents. This was above the analyst estimate for EPS of -58 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024 appeared first on InvestorPlace .
CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program CAMBRIDGE, Mass. , April 11, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise of the pre-funded warrants, in a private placement.
Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Leap Therapeutics (NASDAQ: LPTX ) just reported results for the fourth quarter of 2023. Leap Therapeutics reported earnings per share of -46 cents. This was above the analyst estimate for EPS of -55 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023 appeared first on InvestorPlace .
CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023.
Check out the latest gainers and losers in the stock market today.
Leap Therapeutics, Inc. (Nasdaq:LPTX) announced positive clinical data from the DeFianCe study, showing a 30% objective response rate (ORR) and 93% disease control rate (DCR) in second-line colorectal cancer (CRC) patients treated with DKN-01 plus bevacizumab and chemotherapy. The study revealed the greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients, with a 46% ORR, 100% DCR, and a preliminary median progression-free survival (PFS) of 9.4 months. The company plans to report additional clinical data and subgroup analyses in a conference call on January 23, 2024.